WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016102716) NOVEL HUMANIZED ADAM17 ANTIBODY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/102716    International Application No.:    PCT/EP2016/050029
Publication Date: 30.06.2016 International Filing Date: 04.01.2016
IPC:
A61K 39/395 (2006.01), C07K 16/28 (2006.01), C07K 16/40 (2006.01), A61P 35/00 (2006.01), A61K 39/00 (2006.01)
Applicants: PIERRE FABRE MEDICAMENT [FR/FR]; 45, place Abel Gance 92100 Boulogne-Billancourt (FR)
Inventors: LOWE, Peter; (FR).
BERGER, Sven; (FR).
TESAR, Michael; (DE)
Agent: REGIMBEAU; 20, rue de Chazelles 75847 Paris Cedex 17 (FR)
Priority Data:
14307185.0 24.12.2014 EP
Title (EN) NOVEL HUMANIZED ADAM17 ANTIBODY
(FR) NOUVEAUX ANTICORPS ANTI-ADAM17 HUMANISÉS
Abstract: front page image
(EN)The present disclosure relates to a novel humanized antibody capable of binding to ADAM17 and also the amino and nucleic acid sequences coding for said antibody. From one aspect, the disclosure relates to a novel humanized antibody, or antigen-binding fragments, capable of binding to ADAM17 with anti-tumour activities. The disclosure also comprises the use of said humanized antibody as a drug for the treatment of cancer. Finally, the invention comprises compositions comprising said humanized antibody, alone or in combination or conjugation with other anticancer compounds, and the use of same for the treatment of cancer.
(FR)L'invention concerne un nouvel anticorps humanisé capable de se lier à ADAM-17, ainsi que les séquences d'acides aminés et d'acides nucléiques codant pour ledit anticorps. Dans un aspect, l'invention concerne un nouvel anticorps humanisé ou des fragments de liaison de l'antigène capables de se lier à ADAM-17 et présentant des activités anti-tumorales. L'invention concerne également l'utilisation dudit anticorps humanisé en tant que médicament pour le traitement du cancer. L'invention concerne en outre des compositions comprenant ledit anticorps humanisé, seul ou combiné ou conjugué à d'autres composés anticancéreux, et leur utilisation pour le traitement du cancer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)